TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01985568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential BT
Description: Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Sequential BT will be asked not to begin exercise during months 0-6. They will receive a progressive exercise program and exercise behavior support during months 7-12.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard BT
Description: Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Standard BT will begin exercise immediately upon starting the 6 month dietary weight loss intervention. They will receive a progressive exercise program and exercise behavior support during months 0-6.
Study: NCT02286557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methelphenidate
Description: All participants will undergo 4 weeks of treatment with Methelphenidate and 4 weeks of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methelphenidate
Description: All participants will undergo 4 weeks of treatment with Methelphenidate and 4 weeks of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00082199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 2-30mg, Once daily, 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, Once daily, 12 weeks.
Study: NCT02177474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone based peer support

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone based peer support
Study: NCT03485170

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18F-FDG PET/CT
Description: glucose analogue fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography scan
Study: NCT02913495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Progesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)
Study: NCT03663335

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CFZ533 - MMF - CS
Description: Comparison with standard of care immunosuppression

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CFZ533 - MMF - CS
Description: Comparison with standard of care immunosuppression

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CFZ533 - MMF - CS
Description: Comparison with standard of care immunosuppression
Study: NCT00464425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No Acupuncture
Description: Control
Study: NCT01527682

Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprost, Dorzolamide
Description: * Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)~* Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost
Study: NCT02595086

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic PPG
Description: Laparoscopy assisted pylorus-preserving gastrectomy with D1+ lymphadenectomy (exclude lymph node station No. 5) in Japanese classification.
Study: NCT03663335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus - MMF - +/- corticosteroids
Description: Standard of care immunosupprevive regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus - MMF - +/- corticosteroids
Description: Standard of care immunosupprevive regimen
Study: NCT03383380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Gain-of-function (GOF) PIK3CD mutations lead to PI3Kδ hyperactivity, with the downstream mediators Akt and mTOR hyperphosphorylated. The mammalian/mechanistic target of rapamycin inhibitor rapamycin may be effective to control the progress of this disease.
Study: NCT02596945

Intervention type: DRUG
Intervention: Methoxy polyethylene glycol epoetin beta
Description: Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
Study: NCT00411632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: 400 mg/m\^2 by mouth daily x 28 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily x 28 Days
Study: NCT00911339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10 mg associated with stent genous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80 mg associated with stent genous
Study: NCT05708339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtually fabricated ear prosthesis
Description: virtually designed ear prosthesis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventionally fabricated ear prosthesis
Description: conventionally fabricated ear prosthesis
Study: NCT03800511

Intervention type: DIAGNOSTIC_TEST
Intervention: sliding test
Description: ultrasound detected sliding test before doing repeated caesarean section
Study: NCT00455143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex (Dexmedetomidine)
Description: Dexmedetomidine started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given prior to surgery and continued for 24 hours postoperatively
Study: NCT01211340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTIVE
Description: Assessing Caregivers for Team Intervention via Video Encounters: this intervention uses video technology to bridge geographic distance to empower hospice caregivers to participate in plan of care meetings for their patient
Study: NCT01494597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: oral
Study: NCT05137977

Intervention type: PROCEDURE
Intervention: Intensive Care
Description: Invasive ventilation more than 24hs.
Study: NCT01750905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD-NP
Description: CD-NP 5 ug/kg subcutaneous injection (SQ)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle (D5W) SQ
Study: NCT00408434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017
Description: CS-7017 0.05mg and 1.0mg tablets
Study: NCT02595086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic DG
Description: Laparoscopic distal gastrectomy with D1+ lymphadenectomy in Japanese classification.
Study: NCT02038582

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: POC CD4 Testing
Description: Point of Care CD4 testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: POC CD4 Testing
Description: Point of Care CD4 testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: POC CD4 Testing
Description: Point of Care CD4 testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CD4 Referral
Description: Referral to CD4 testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CD4 Referral
Description: Referral to CD4 testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CD4 Referral
Description: Referral to CD4 testing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lay Counselor Follow-up
Description: Follow-up from a lay counselor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lay Counselor Follow-up
Description: Follow-up from a lay counselor
Study: NCT00683839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief tobacco counseling
Description: Public health dental professionals provide brief counseling during routine visits based on the Clinical Practice Guidelines 5 As (Ask, Advise, Assess, Assist, Arrange), including offering free Nicotine Replacement Therapy and referral to a Tobacco Quit Line. Pharmacologic: nicotine patch or lozenge maximum 12 week course.
Study: NCT03803436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplant
Description: Liver transplant from cadaveric donors
Study: NCT02038582

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lay Counselor Follow-up
Description: Follow-up from a lay counselor
Study: NCT03803436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: mFOLFOX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Panitumumab
Study: NCT02038582

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Accompaniment
Description: Accompaniment to the clinic by a counselor
Study: NCT02331017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech perception tests and self-rating questionnaire
Description: Speech perception test results and self-rating questionnaire scores will be analyzed by means of non-parametric statistical tests. The statistical tests will be chosen in accordance with the number and type of variables in each test. Correlation between audiological variables (aided and unaided hearing thresholds in the non implanted ear, aided speech perception abilities in the HA-alone condition) and the bilateral-bimodal benefit will be examined. Moreover, possible relationship between self-rating questionnaire scores and speech perception test results will be assessed.
Study: NCT00387036

Intervention type: DRUG
Group type: OTHER
Intervention: Fluticasone
Description: fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Fluticasone
Description: fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: Placebo
Description: Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
Study: NCT02229461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium (Aleve, BAY117031)
Description: Naproxen sodium 220 mg qd or bid
Study: NCT00126620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study: NCT01778101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: lansoprazole 1mg/kg twice a day for 14days
Study: NCT00595816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical training and counselling
Description: Neuromuscular training program 3 times per week 30 minutes per session and counselling on back problems and other musculosceletal injuries
Study: NCT01545440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab
Description: subcutaneous dose every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab
Description: subcutaneous dose every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab
Description: subcutaneous dose every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous dose every 4 weeks
Study: NCT02634827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Given PO
Study: NCT02038582

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Accompaniment
Description: Accompaniment to the clinic by a counselor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Referral
Description: Referral to clinic

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Referral
Description: Referral to clinic
Study: NCT03304873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin
Description: Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment
Description: The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
Study: NCT02770300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm Light Exoskeleton Rehab Station (ALEx RS)
Description: ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm Light Exoskeleton Rehab Station (ALEx RS) - automatically personalized
Description: ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress. The movements to be performed by the patient are automatically decided by the exoskeleton.
Study: NCT03637517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265-TPGS 34% SDD, 400 mg fasted
Description: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSM265-TPGS 34% SDD, 400 mg fed
Description: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSM265 25% SDD, 400 mg fasted
Description: Reference formulation used in early clinical trials.
Study: NCT04113525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoRegulator™ System
Description: Paired transcutaneous spinal and peripheral nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MyoRegulator™ System
Description: Paired transcutaneous spinal and peripheral nerve stimulation
Study: NCT00774683

Intervention type: DRUG
Intervention: Raltegravir (Isentress®)
Description: 400 mg p.o. BID x 7 days
Study: NCT02038582

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS Reminder
Description: SMS reminder for male circumcision
Study: NCT00941122

Intervention type: DEVICE
Intervention: Eluted Swab
Description: Comparison of Eluted Swab with AMIES swab for detection of MRSA/VRE
Study: NCT02038582

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Circumcision Promotion
Description: Promotion of male circumcision at the time of HIV testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: POC VL
Description: POC VL testing for HIV infected persons on ART

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory based VL assay
Description: Laboratory based viral load testing for HIV infected persons on ART
Study: NCT02050087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simple sling.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral brace
Study: NCT03779087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10d TL quadruple therapy
Description: esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10d AL quadruple therapy
Description: esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.
Study: NCT00903305

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical chart review
Study: NCT00126620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study: NCT01274156

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEDISPEC treatment probe
Description: 300 shocks in 5 different anatomical locations of the penis.
Study: NCT01808430

Intervention type: PROCEDURE
Intervention: VATS for confirmed non-small cell lung cancer (NSCLC)
Description: Video-Assisted Thoracoscopic Surgery for NSCLC patients
Study: NCT04931433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine
Description: Group A will receive 1.5mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion will be halved to 1mg/kg/hour until the end of surgery. The same rate will be infused in the recovery room for another half an hour before participant is discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Group B will receive saline of similar volume and rate as Group A
Study: NCT02229461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: ASA 81 mg qd
Study: NCT00575055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 0.5 mg/kg
Description: given by infusion every 13 weeks for a total of 6 infusions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: given by infusion every 13 weeks for a total of 6 infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 1.0 m/kg
Description: given by infusion every 13 weeks for a total of 6 infusions.
Study: NCT03048656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: static posturography
Description: The measurement of the weight distribution and the static posturography was performed on the balance platform Good Balance by Metitur . The device is comprised of the triangular force platform with electronic system and computer software. The body weight distribution was evaluated in the upright standing with eyes open, feet placed 20 cm from each other.The individual stood motionlessly for 15 s, then the measurement was recorded. The static posturography was performed with 3 various positions of feet, both with eyes open and eyes closed. (1) Position : normal standing - an upright standing with feet placed parallel 20 cm apart for 30 s. (2) Position: tandem - a stance with one foot placed ahead of the other. for 20 s. (3) Position: one leg standing: stance on the one leg for 20 s.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: static posturography
Description: The measurement of the weight distribution and the static posturography was performed on the balance platform Good Balance by Metitur . The device is comprised of the triangular force platform with electronic system and computer software. The body weight distribution was evaluated in the upright standing with eyes open, feet placed 20 cm from each other.The individual stood motionlessly for 15 s, then the measurement was recorded. The static posturography was performed with 3 various positions of feet, both with eyes open and eyes closed. (1) Position : normal standing - an upright standing with feet placed parallel 20 cm apart for 30 s. (2) Position: tandem - a stance with one foot placed ahead of the other. for 20 s. (3) Position: one leg standing: stance on the one leg for 20 s.
Study: NCT03895983

Intervention type: PROCEDURE
Intervention: Percutaneous primary coronary intervention
Description: Percutaneous primary coronary intervention

Intervention type: PROCEDURE
Intervention: Percutaneous primary coronary intervention
Description: Percutaneous primary coronary intervention
Study: NCT01274156

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MEDISPEC Sham Probe
Description: Sham probe applied same as treatment probe without energy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEDISPEC Low intensity shock waves
Description: Treatment parameters will be as follows: Intensity: 0.09 mj/mm2 ,300 shocks per site, on 5 penile anatomical sites. Total number of shock waves: 1500/ session Frequency of 120/min
Study: NCT03098173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early colonoscopy
Description: Performance of prepared colonoscopy within 24 h of arrival

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective colonoscopy
Description: Performance of prepared colonoscopy between 24 and 96 h after arrival
Study: NCT00903305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical chart review

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fatigue assessment and management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatigue assessment and management
Study: NCT01274156

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Probe does not deliver energy but creates same noise and sensation of active probe
Study: NCT01207518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: This group of healthcare organizations will be given the Guide, web-based tools and access to a Guide facilitator throughout the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group will provide their immunization rates for the base and study years and will provide information on their campaign activities. No other intervention will be provided.